4502 — Takeda Pharmaceutical Co Share Price
Last trade - 00:00- ¥7tn
- ¥11tn
- ¥4tn
- 59
- 59
- 100
- 87
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 28.89 | ||
| PEG Ratio (f) | 0.72 | ||
| EPS Growth (f) | 67.11% | ||
| Dividend Yield (f) | 4.74% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.9 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 8.41 | ||
| Price to Sales | 1.46 | ||
| EV to EBITDA | 9.43 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 3.13% | ||
| Return on Equity | 2.94% | ||
| Operating Margin | 8.9% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 3,291,188 | 3,197,812 | 3,569,006 | 4,027,478 | 4,263,762 | 4,606,073 | 4,582,822 | 15.25% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -4.83 | +21.26 | +50.12 | +8.84 | -20.77 | -47.91 | +67.11 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
Directors
- Masahiro Sakane CHM (80)
- Christophe Weber PRE (54)
- Costa Saroukos CFO (50)
- Andrew Plump OTH (55)
- Masato Iwasaki DRC (62)
- Olivier Bohuon IND (62)
- Jean-Luc Butel IND (64)
- Ian Clark IND (60)
- Yoshiaki Fujimori IND (70)
- Steven Gillis IND (68)
- Koji Hatsukawa IND (69)
- Emiko Higashi IND (62)
- Masami Iijima IND (70)
- Shiro Kuniya IND (64)
- Michel Orsinger IND (63)
- Toshiyuki Shiga IND (68)
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 29th, 1925
- Public Since
- May 16th, 1949
- No. of Shareholders
- 575,272
- No. of Employees
- 49,281
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 1,585,191,249
- Address
- 4F, 2-1-1, Nihombashihon-cho, CHUO-KU, 103-8668
- Web
- https://www.takeda.com/
- Phone
- +81 332782111
- Auditors
- KPMG AZSA LLC
Latest News for 4502
Upcoming Events for 4502
Full Year 2025 Takeda Pharmaceutical Co Ltd Earnings Release
Takeda Pharmaceutical Co Ltd Annual Shareholders Meeting
Q1 2026 Takeda Pharmaceutical Co Ltd Earnings Release
Similar to 4502
ASKA Pharmaceutical Holdings Co
Tokyo Stock Exchange
Astellas Pharma
Tokyo Stock Exchange
Astena Holdings Co
Tokyo Stock Exchange
CanBas Co
Tokyo Stock Exchange
CellSeed
Tokyo Stock Exchange
FAQ
As of Today at 23:33 UTC, shares in Takeda Pharmaceutical Co are trading at ¥4,212. This share price information is delayed by 15 minutes.
Shares in Takeda Pharmaceutical Co last closed at ¥4,212 and the price had moved by +3.51% over the past 365 days. In terms of relative price strength the Takeda Pharmaceutical Co share price has outperformed the Nikkei 225 Index by +13.05% over the past year.
The overall consensus recommendation for Takeda Pharmaceutical Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Takeda Pharmaceutical Co dividend yield is 4.56% based on the trailing twelve month period.
Last year, Takeda Pharmaceutical Co paid a total dividend of ¥192, and it currently has a trailing dividend yield of 4.56%.Looking ahead, the next dividend pay date is 2025-06-01.
We do not have data on when Takeda Pharmaceutical Co is to next pay dividends. The historic dividend yield on Takeda Pharmaceutical Co shares is currently 4.56%.
To buy shares in Takeda Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of ¥4,212, shares in Takeda Pharmaceutical Co had a market capitalisation of ¥7tn.
Here are the trading details for Takeda Pharmaceutical Co:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4502
Based on an overall assessment of its quality, value and momentum Takeda Pharmaceutical Co is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Takeda Pharmaceutical Co is ¥4,980. That is 18.23% above the last closing price of ¥4,212.
Analysts covering Takeda Pharmaceutical Co currently have a consensus Earnings Per Share (EPS) forecast of ¥87 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Takeda Pharmaceutical Co. Over the past six months, its share price has outperformed the Nikkei 225 Index by +10.45%.
As of the last closing price of ¥4,212, shares in Takeda Pharmaceutical Co were trading -0.4% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Takeda Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is 28.89. The shares last closed at ¥4,212.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Takeda Pharmaceutical Co's management team is headed by:
- Masahiro Sakane - CHM
- Christophe Weber - PRE
- Costa Saroukos - CFO
- Andrew Plump - OTH
- Masato Iwasaki - DRC
- Olivier Bohuon - IND
- Jean-Luc Butel - IND
- Ian Clark - IND
- Yoshiaki Fujimori - IND
- Steven Gillis - IND
- Koji Hatsukawa - IND
- Emiko Higashi - IND
- Masami Iijima - IND
- Shiro Kuniya - IND
- Michel Orsinger - IND
- Toshiyuki Shiga - IND